Quote | Dermata Therapeutics Inc. (NASDAQ:DRMA)
Last: | $2.23 |
---|---|
Change Percent: | 3.14% |
Open: | $2.16 |
Close: | $2.23 |
High: | $2.31 |
Low: | $2.15 |
Volume: | 13,829 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Dermata Therapeutics Inc. (NASDAQ:DRMA)
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
2024-05-17 01:24:22 ET More on Dermata Therapeutics Seeking Alpha’s Quant Rating on Dermata Therapeutics Historical earnings data for Dermata Therapeutics Financial information for Dermata Therapeutics Read the full article on Seeking Alpha For...
Message Board Posts | Dermata Therapeutics Inc. (NASDAQ:DRMA)
Subject | By | Source | When |
---|---|---|---|
Well it did it | Triple nickle | investorshub | 05/12/2023 1:17:38 PM |
Gotta get thru 3.30 | Triple nickle | investorshub | 05/12/2023 10:20:40 AM |
Dermata Therapeutics Provides Corporate Update and Reports First | subslover | investorshub | 05/12/2023 10:13:57 AM |
great news | Invest-in-America | investorshub | 05/11/2023 10:23:41 PM |
MomentumIts gaining | subslover | investorshub | 05/11/2023 6:07:34 PM |
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Website:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...